Zeshaan Maan
Plastic and Reconstructive Surgery · San Jose, CANPI 1174907083
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. TELA Bio, Inc. accounts for 69.4% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $11,280, more than ten times the $384 reported in 2021.
Across 74 payments — averaging $227.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TELA Bio, Inc.$12K
- AbbVie$1K
- Evolution Surgical, Inc$1K
- Musculoskeletal Transplant Foundation Inc.$1K
- Axogen$616
- Checkpoint Surgical, Inc$157
- plus $696 from 9 others
What the payments were for
- Consulting fees$7,70046%
- Travel & lodging$3,12819%
- Food & beverage$4,78928%
- Education$1,2007%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TELA Bio, Inc. | 28 | $11,667 |
| AbbVie(2 entities) | 17 | $1,405 |
| Evolution Surgical, Inc | 1 | $1,200 |
| Musculoskeletal Transplant Foundation Inc. | 7 | $1,076 |
| Axogen | 4 | $616 |
| Checkpoint Surgical, Inc | 1 | $157 |
| Davol Inc. | 1 | $146 |
| Johnson & Johnson | 1 | $137 |
| Revance Therapeutics, Inc. | 2 | $104 |
| Mentor Worldwide LLC | 4 | $96 |
| Motiva USA, LLC | 3 | $68 |
| Vertex | 2 | $51 |
| Biotissue Holdings Inc. | 1 | $41 |
| RTI Surgical, Inc | 1 | $32 |
| Smith+Nephew | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,817 in reported general payments places this provider in the 85th percentile of 349 plastic and reconstructive surgery providers in California.
See all plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 13 | $157 |
| Gabapentin | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in San Jose
- Mark SuskiThousand Oaks$294K
- Corey MaasSan Francisco$286K
- Arian MowlaviLaguna Beach$250K
- Charles LeeSan Francisco$200K
- David SieberSan Francisco$195K
- David KulberLos Angeles$194K
- Matthew NykielUpland$181K
- Subhas GuptaLoma Linda$178K
- Jeffrey HammoudehLos Angeles$159K
- Geoffrey GurtnerPalo Alto$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.